Biogen Idec

Michael J. Fox Foundation unites industry groups for research tool development

Friday, September 13, 2013 01:07 PM

The Michael J. Fox Foundation for Parkinson's research (MJFF) has launched the Parkinson's Disease Research Tools Consortium. MJFF and seven industry partners have organized to grow the Foundation's ongoing efforts to better understand existing tools—such as preclinical models, antibodies and cell lines—and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.

More... »

Amicus Therapeutics, Biogen Idec collaborate for Parkinson's disease

Wednesday, September 11, 2013 01:38 PM

Amicus Therapeutics, a biopharmaceutical company developing therapies for rare and orphan diseases, is collaborating with Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's.

More... »

Biogen Idec, Isis Pharmaceuticals collaborate on neurological disorders

Monday, September 9, 2013 12:07 PM

Biogen Idec and Isis Pharmaceuticals have entered a broad, six-year research collaboration to leverage antisense technology to advance the treatment of neurological diseases. The agreement combines Biogen Idec's experience in neurology with Isis' antisense technology to develop novel therapies to treat neurological disorders.

More... »

Perrigo to acquire Elan for $8.6 billion

Monday, July 29, 2013 11:02 AM

Allegan, Mich.-based Perrigo, a global provider of healthcare products and Elan, a Dublin-based biotechnology company, have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland (“New Perrigo”).

More... »

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

University of Edinburgh, Biogen Idec partner

Wednesday, July 24, 2013 02:35 PM

The University of Edinburgh and Massachusetts-based biotech Biogen Idec have partnered to research multiple sclerosis and motor neurone disease and identify drug compounds for potential treatments. The initiative is funded by Biogen Idec, which develops therapies for neurological disorders and has a portfolio of treatments for patients with multiple sclerosis.

More... »

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

Elan closes Tysabri collaboration transaction with Biogen Idec

Wednesday, April 3, 2013 03:17 PM

Elan, a biotechnology company based in Ireland, has closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec, which was originally announced on February 6, 2013.

More... »

FDA approves Biogen Idec’s Tecfidera for multiple sclerosis

Friday, March 29, 2013 01:44 PM

The FDA has approved Biogen Idec’s Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).

More... »

Merck, Samsung Bioepis ink biosimilars development agreement

Friday, February 22, 2013 11:45 AM

Global healthcare company Merck and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, entered into an agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates.

More... »